Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Phase II Clinical Trial to Evaluate the Effect of Avastin in Combination With Neoadjuvant Treatment Regimens on the Molecular and Metabolic Characteristics and Changes in the Primary Tumors With Reference to the Obtained Responses in Patients With Large Primary HER2 Negative Breast Cancers

Next Previous
Search
Trial Profile

A Multicenter, Randomized, Phase II Clinical Trial to Evaluate the Effect of Avastin in Combination With Neoadjuvant Treatment Regimens on the Molecular and Metabolic Characteristics and Changes in the Primary Tumors With Reference to the Obtained Responses in Patients With Large Primary HER2 Negative Breast Cancers

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Aromatase inhibitors; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil; Paclitaxel
  • Indications Adenocarcinoma; Early breast cancer; HER2 negative breast cancer
  • Focus Therapeutic Use
  • Acronyms Neo-Ava; NeoAva
  • Sponsors Roche

    • Most Recent Events

    • 19 Oct 2023 Planned number of patients changed from 150 to 200.
    • 19 Apr 2023 Results deriving FFPE tissue sections from patients before, during, and after treatment , pursuing information on spatial organization of cellular phenotypes expressing selected cancer related proteins including our nine ViRP proteinspresented at the 114th Annual Meeting of the American Association for Cancer Research
    • 05 Jan 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top